Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer

Veterinary Immunology and Immunopathology

Volumn 134, Issue 1-2, 2010, Pages 132-137

  Vannucci, Laura ^a   Chiuppesi, Flavia ^a   di Martino, Fabio ^b   Caligo, Maria Adelaide ^c   Bevilacqua, Generoso ^c   Pistello, Mauro ^a  

^a Retrovirus Center   (Italy)

^b School of Veterinary of Pisa   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Breast cancer; Breast cancer associated gene (BRCA1); Feline immunodeficiency virus (FIV); Gene therapy; Lentiviral vector

Indexed keywords

BRCA1 PROTEIN; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ARTICLE; BREAST CANCER; BREAST CELL; CELL STRAIN 3T3; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FELINE IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IONIZING RADIATION; NONHUMAN; NUCLEOTIDE SEQUENCE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CLONING, MOLECULAR; DNA, RECOMBINANT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENES, BRCA1; GENES, BRCA2; GENETIC VECTORS; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; TARGETED GENE REPAIR; TRANSDUCTION, GENETIC;

FELINE IMMUNODEFICIENCY VIRUS;

EID: 75749140853     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.10.018     Document Type: Article

References (28)

1. Baer R., and Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12 (2002) 86-91
2. Barraza R.A., and Poeschla E.M. Human gene therapy vectors derived from feline lentiviruses. Vet. Immunol. Immunopathol. 123 (2008) 23-31
3. Bouard D., Alazard-Dany N., and Cosset F.L. Viral vectors: from virology to transgene expression. Br. J. Pharmacol. (2008) (Epub ahead of print)
4. Carvalho M.A., Couch F.J., and Monteiro A.N. Functional assays for BRCA1 and BRCA2. Int. J. Biochem. Cell Biol. 39 (2007) 298-310
5. Chang L.J., and He J. Retroviral vectors for gene therapy of AIDS and cancer. Curr. Opin. Mol. Ther. 3 (2001) 468-475
6. Consiglio A., Quattrini A., Martino S., Bensadoun J.C., Dolcetta D., Trojani A., Benaglia G., Marchesini S., Cestari V., Oliverio A., Bordignon C., and Naldini L. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 7 (2001) 310-316
7. Deng C.X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34 (2006) 1416-1426
8. James C.R., Quinn J.E., Mullan P.B., Johnston P.G., and Harkin D.P. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12 (2007) 142-150
9. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
10. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
11. Lever A.M., Strappe P.M., and Zhao J. Lentiviral vectors. J. Biomed. Sci. 11 (2004) 439-449
12. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
13. Narod S.A., Brunet J.S., Ghadirian P., Robson M., Heimdal K., Neuhausen S.L., Stoppa-Lyonnet D., Lerman C., Pasini B., de los Rios P., Weber B., and Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356 (2000) 1876-1881
14. Osborne C., Wilson P., and Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9 (2004) 361-377
15. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
16. Pistello M., Bonci F., Flynn J.N., Mazzetti P., Isola P., Zabogli E., Camerini V., Matteucci D., Freer G., Pelosi P., and Bendinelli M. AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens. J. Virol. 80 (2006) 8856-8868
17. Pistello M., Moscardini M., Mazzetti P., Bonci F., Zaccaro L., Isola P., Freer G., Specter S., Matteucci D., and Bendinelli M. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 298 (2002) 84-95
18. Pistello M., Vannucci L., Ravani A., Bonci F., Chiuppesi F., Del Santo B., Freer G., and Bendinelli M. Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes. Genet. Vaccines Ther. 5 (2007) 8
19. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van't Veer L., Garber J.E., Evans G.R., Narod S.A., Isaacs C., Matloff E., Daly M.B., Olopade O.I., and Weber B.L. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22 (2004) 1055-1062
20. Ricks D.M., Kutner R., Zhang X.Y., Welsh D.A., and Reiser J. Optimized lentiviral transduction of mouse bone marrow-derived mesenchymal stem cells. Stem. Cells Dev. 17 (2008) 441-450
21. Rodriquez E., and Domchek S.M. The prevention of hereditary breast cancer. Semin. Oncol. 34 (2007) 401-405
22. Romano G., Claudio P.P., Tonini T., and Giordano A. Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications. Eur. J. Dermatol. 13 (2003) 424-429
23. Scully R., Ganesan S., Vlasakova K., Chen J., Socolovsky M., and Livingston D.M. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol. Cell 4 (1999) 1093-1099
24. Teng L.S., Zheng Y., and Wang H.H. BRCA1/2 associated hereditary breast cancer. J. Zhejiang Univ. Sci. B 9 (2008) 85-89
25. Tomlinson G.E., Chen T.T., Stastny V.A., Virmani A.K., Spillman M.A., Tonk V., Blum J.L., Schneider N.R., Wistuba I.I., Shay J.W., Minna J.D., and Gazdar A.F. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 58 (1998) 3237-3242
26. Willett B.J., Cannon C.A., and Hosie M.J. Expression of CXCR4 on feline peripheral blood mononuclear cells: effect of feline immunodeficiency virus infection. J. Virol. 77 (2003) 709-712
27. Wilson C.A., and Cichutek K. The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol. Biol. 506 (2009) 477-488
28. Zhang J., and Powell S.N. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol. Cancer Res. 3 (2005) 531-539